Evaluation of pneumococcal surface protein a as a vaccine antigen against secondary streptococcus pneumoniae challenge during influenza a infection

Research output: Contribution to journalArticle


  • Sean Roberts
  • Clare M. Williams
  • Sharon L. Salmon
  • Jesse L. Bonin
  • Dennis W. Metzger
  • Yoichi Furuya

External Institution(s)

  • Albany Medical College


Original languageEnglish (US)
Article number146
Issue number4
StatusPublished - Dec 2019


Secondary bacterial pneumonia is responsible for significant morbidity and mortality during seasonal and pandemic influenza. Due to the unpredictability of influenza A virus evolution and the time-consuming process of manufacturing strain-specific influenza vaccines, recent efforts have been focused on developing anti-Streptococcus pneumoniae immunity to prevent influenza-related illness and death. Bacterial vaccination to prevent viral-bacterial synergistic interaction during co-infection is a promising concept that needs further investigation. Here, we show that immunization with pneumococcal surface protein A (PspA) fully protects mice against low-dose, but not high-dose, secondary bacterial challenge using a murine model of influenza A virus-S. pneumoniae co-infection. We further show that immunization with PspA is more broadly protective than the pneumococcal conjugate vaccine (Prevnar). These results demonstrate that PspA is a promising vaccine target that can provide protection against a physiologically relevant dose of S. pneumoniae following influenza infection.

    Research areas

  • Influenza-pneumococcal co-infection, Pneumococcal surface protein A, Pneumococcal vaccination, Prevnar, Streptococcus pneumoniae